Abstract

Select Medical is scheduled to report fiscal first-quarter results on April 30, 2026 Post Market, with investors watching for revenue around 1.41 billion US dollars and adjusted EPS near 0.46 as the company updates progress on margins and segment mix following a softer fourth quarter.

Market Forecast

The market’s base case for the upcoming quarter points to revenue of approximately 1.41 billion US dollars, a year-over-year increase of 1.49%, and adjusted EPS around 0.46, implying a 0.40% year-over-year uptick. Forecast EBIT stands near 115.39 million US dollars, which implies a 7.61% year-over-year decline, suggesting the consensus expects modest revenue expansion but some pressure on operating profitability; no formal guidance has been provided for gross margin or net margin.

Within the company’s operating mix, recent results show a balanced revenue contribution across hospital-based and outpatient rehabilitation, with the hospital-based complex care units remaining the largest single driver. The most promising near-term contributor appears to be outpatient rehabilitation clinics given consistent volumes and scheduling leverage, with the segment contributing roughly 329.09 million US dollars last quarter based on mix; comparable-year growth for this segment was not disclosed, though the company-level revenue growth baseline was 6.41% year over year in the preceding quarter.

Last Quarter Review

In the latest reported quarter, Select Medical posted revenue of 1.40 billion US dollars, a gross profit margin of 15.63%, GAAP net profit attributable to shareholders of 20.17 million US dollars, a net profit margin of 1.44%, and adjusted EPS of 0.16, which represented a 223.08% year-over-year increase. Revenue grew 6.41% year over year and exceeded consensus by 32.89 million US dollars, while adjusted EPS trailed consensus by 0.07, highlighting a gap between revenue resilience and bottom-line conversion. By segment, hospital-based critical illness recovery facilities accounted for about 45.44% of quarterly revenue (roughly 634.64 million US dollars), inpatient rehabilitation hospitals contributed about 23.64% (approximately 330.14 million US dollars), outpatient rehabilitation clinics contributed about 23.56% (roughly 329.09 million US dollars), and other services comprised about 7.36% (approximately 102.76 million US dollars), with company-level year-over-year revenue growth at 6.41%.

Current Quarter Outlook

Hospital-Based Critical Illness Recovery Facilities

The hospital-based critical illness recovery facilities remain the largest revenue contributor, inferred at roughly 634.64 million US dollars last quarter based on revenue mix. For the current quarter, the key question is whether unit economics can defend margins as consensus points to a mild top-line increase but a year-over-year contraction in EBIT. Wage inflation, shift differentials, and contract labor normalization are central variables; every incremental improvement in labor productivity has a leveraged effect on EBIT because this segment carries high fixed costs tied to staffing and facilities. Rates and case mix also matter: payer mix shifts toward commercial payers or favorable rate resets tend to support revenue-per-episode, whereas a tilt toward lower-yield cases compresses contribution margins even when volumes are stable.

Operational throughput—census stability and efficient transitions—will be another pivot. Length-of-stay discipline and discharge management tie into capacity utilization and revenue capture; achieving steady bed occupancy without sacrificing case acuity supports both revenue and gross margin. Against this backdrop, the consensus EBIT decline of 7.61% year over year suggests the market embeds conservatism on labor costs and throughput in hospital-based settings despite slight revenue growth expectations. The path to upside would be a mix of staffing leverage (lower premium pay, improved scheduling), stable census, and better-than-expected rate capture, which collectively could offset input cost pressure and help gross margin trend toward or above last quarter’s 15.63% baseline.

Outpatient Rehabilitation Clinics

Outpatient rehabilitation clinics appear to offer the best near-term growth optionality due to schedule density and comparatively variable cost structures, with last quarter’s contribution estimated at about 329.09 million US dollars based on mix. In the current quarter, visit growth, referral funnel quality, and pricing discipline are the three operational levers to watch most closely. A tighter scheduling cadence and reduced no-show rates can lift revenue without materially raising fixed overhead, and they can bolster gross contribution even if wage rates remain elevated. In addition, channel quality—orthopedic and post-acute referrals—tends to support higher-yield visit mixes, which helps maintain revenue-per-visit while limiting visit-level cost creep.

The forecast framework—a 1.49% year-over-year revenue increase for the quarter and a near-flat EPS progression—implies that any upside surprise will likely come from the outpatient unit’s throughput and incremental margin. If scheduling and referral execution are in line, outpatient rehabilitation can provide a counterbalance to hospital labor headwinds through mix and scalability. The segment’s ability to convert incremental visits into margin will also help explain whether gross margin can improve from the 15.63% level seen last quarter. Even modest same-center visit growth combined with measured price increases can translate into a disproportionate contribution to EBIT relative to revenue, provided support staffing is aligned to demand and premium labor is contained.

Key Stock Price Drivers This Quarter

Three factors are likely to dominate equity performance in the near term: the trajectory of operating leverage versus wage inflation, the implications of the proposed acquisition by a consortium led by the Executive Chairman, and how the quarterly print calibrates investor confidence in forward earnings. First, at the consolidated level, the difference between the revenue estimate rising 1.49% year over year and EBIT forecast declining 7.61% implies that labor and other operating costs could absorb more of the top line. If the company demonstrates that labor productivity and premium-pay utilization improved sequentially, investors will be inclined to view the EBIT outlook as conservative, potentially supporting valuation. Conversely, if premium pay remains sticky or payer/pricing dynamics limit revenue-per-episode or revenue-per-visit, the market may extrapolate a narrower margin trajectory into subsequent quarters.

Second, the management-led buyout proposal and related financing developments are part of the narrative investors are tracking this quarter. Updates on the process—including timing, conditions, and interim operating flexibility—can shape how investors interpret near-term earnings in the context of potential transaction milestones. Rating changes issued by sell-side institutions in the first quarter of 2026 indicate that some analysts recalibrated their stance to a more neutral posture amid the evolving situation, with a preference to monitor execution and deal progress. This context means the quarter’s results will be assessed not only on the absolute numbers, but also on how they inform the transaction backdrop, deleveraging prospects, and free cash conversion.

Third, the earnings mix matters. The consensus-adjusted EPS of roughly 0.46 implies only a 0.40% year-over-year increase despite revenue growth, pointing to margin as the swing factor. Investors will look for signals in patient throughput, payer dynamics, and staffing expense run rates to infer whether the company can expand gross profit above the 15.63% level and stabilize net margin above the prior 1.44%. If management’s commentary aligns with measured cost discipline and steady demand across both hospital-based and outpatient settings, the stock could respond positively even to an inline print; if not, the market may lean toward the caution already reflected in the EBIT forecast.

Analyst Opinions

Across opinions published between January 1, 2026 and April 23, 2026, the majority view leans cautious to negative: two bearish or neutral-leaning actions versus one bullish stance, a 67% to 33% split. On March 3, 2026, RBC downgraded Select Medical to Sector Perform from Outperform and reduced its price target to 16.50 US dollars from 19.00 US dollars, citing a more balanced risk-reward in light of evolving company-specific developments. On March 4, 2026, Deutsche Bank followed by downgrading the shares to Hold from Buy, adjusting its price target to 16.50 US dollars from 16.20 US dollars, indicating limited near-term upside until visibility improves.

This tilt toward caution mirrors the consensus modeling: revenue is expected to increase by 1.49% year over year while EBIT is projected to decline by 7.61%, a configuration that flags cost pressure and margin sensitivity. Sell-side strategists are therefore focusing on sustainability of labor normalization, contribution from outpatient throughput, and pricing discipline. With adjusted EPS modeled at approximately 0.46—just 0.40% above the prior-year quarter—many analysts prefer to see evidence of operating leverage before revisiting more constructive stances. The management-led acquisition discussions add a layer of uncertainty; some institutions have indicated that the transaction backdrop and related financing developments warrant a neutral posture pending updates, which aligns with the downgrade actions.

In framing this quarter, analysts are likely to scrutinize three proof points. First, whether premium labor and overtime expenses normalize in line with internal targets, thereby allowing gross margin to track above the 15.63% print from last quarter. Second, whether patient volumes and revenue-per-episode/visit across both hospital-based and outpatient segments support the 1.49% top-line growth expectation without further diluting operating margin. Third, whether free cash flow and working capital trends leave room for debt service and flexibility amid the transaction context, an aspect that subtly informs sentiment even though it is not explicitly captured in quarterly EPS. In sum, while one institution maintained a Buy into late February, the preponderance of updated opinions since early March emphasizes a watchful stance; until the company prints evidence of margin traction and provides additional clarity on the strategic process, the market’s institutional lens is cautious.